NASDAQ:HTGMHTG Molecular Diagnostics Stock Price, Forecast & News

$0.70

-0.01 (-1.41 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.65

Now: $0.70▼

$0.78

50-Day Range

$0.33

MA: $0.43▼

$0.71

52-Week Range

$0.27

Now: $0.70▼

$2.28

Volume8.14 million shs

Average Volume6.81 million shs

Market Capitalization$43.55 million

P/E RatioN/A

Dividend YieldN/A

Beta1.78

HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL Cell of Origin Assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA Whole-Transcriptome Assay; HTG EdgeSeq DLBCL Cell of Origin Assay EU; HTG EdgeSeq ALKPlus Assay EU; HTG EdgeSeq EGFR, KRAS and BRAF Mutation Assay; and HTG EdgeSeq Precision Immuno-Oncology Panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; governing agreement with QIAGEN Manchester Limited; development and professional services agreement with Invetech PTY Ltd; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
HTG Molecular Diagnostics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.18, HTG Molecular Diagnostics has a potential upside of 67.9% from its current price of $0.70.
Amount of Analyst Coverage
HTG Molecular Diagnostics has only been the subject of 3 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
HTG Molecular Diagnostics has received 307 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
HTG Molecular Diagnostics has received 269 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
HTG Molecular Diagnostics has received 53.30% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote “Outperform” if you believe HTGM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HTGM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
HTG Molecular Diagnostics does not currently pay a dividend.
Dividend Growth
HTG Molecular Diagnostics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, HTG Molecular Diagnostics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.60% of the stock of HTG Molecular Diagnostics is held by insiders.
Percentage Held by Institutions
Only 28.69% of the stock of HTG Molecular Diagnostics is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for HTG Molecular Diagnostics are expected to grow in the coming year, from ($0.31) to ($0.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of HTG Molecular Diagnostics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of HTG Molecular Diagnostics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
HTG Molecular Diagnostics has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.34 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Analytical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:HTGM

Previous Symbol

CUSIPN/A

CIK1169987

Webwww.htgmolecular.com

Phone877-289-2615

Debt

Debt-to-Equity Ratio0.33

Current Ratio4.61

Quick Ratio4.42

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$19.20 million

Price / Sales2.27

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.41 per share

Price / Book1.71

Profitability

EPS (Most Recent Fiscal Year)($0.51)

Net Income$-19,300,000.00

Net Margins-106.35%

Return on Equity-90.50%

Return on Assets-44.79%

Miscellaneous

Employees107

Outstanding Shares62,210,000

Market Cap$43.55 million

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive HTGM News and Ratings via Email

Sign-up to receive the latest news and ratings for HTGM and its competitors with MarketBeat's FREE daily newsletter.

HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions

How has HTG Molecular Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

HTG Molecular Diagnostics' stock was trading at $0.3942 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HTGM shares have increased by 77.6% and is now trading at $0.70. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of HTG Molecular Diagnostics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for HTG Molecular Diagnostics.

When is HTG Molecular Diagnostics' next earnings date?

HTG Molecular Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for HTG Molecular Diagnostics.

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) released its earnings results on Wednesday, May, 13th. The medical research company reported ($0.08) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.01. The medical research company had revenue of $2.23 million for the quarter, compared to analyst estimates of $2.28 million. HTG Molecular Diagnostics had a negative return on equity of 90.50% and a negative net margin of 106.35%. View HTG Molecular Diagnostics' earnings history.

What price target have analysts set for HTGM?

4 equities research analysts have issued 1 year price objectives for HTG Molecular Diagnostics' stock. Their forecasts range from $0.70 to $1.50. On average, they anticipate HTG Molecular Diagnostics' stock price to reach $1.18 in the next twelve months. This suggests a possible upside of 67.9% from the stock's current price. View analysts' price targets for HTG Molecular Diagnostics.

What are Wall Street analysts saying about HTG Molecular Diagnostics stock?

Here are some recent quotes from research analysts about HTG Molecular Diagnostics stock:

1. According to Zacks Investment Research, "HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. " (5/22/2020)
2. Canaccord Genuity analysts commented, "We were pleased to host newer HTG CEO John Lubniewski and CFO Conference last week in Boston. Our key takeaways: (1) HTG is making a bigger push to develop and launch novel diagnostic test launches in breast and lung cancer; (2) HTG is not getting any credit in its stock price for strong 80%+ Y/Y growth in its base RUO profiling business; and (3) HTG has taken adverse lumps" because they haven’t converted a CDx yet (yet they have over 70 active global pharma programs). We reiterate our BUY rating and trim our PT to $3, which we would be inclined to raise should HTG hit" on one of its pharma collaborations. EdgeSeq Breast Total Lung." (8/13/2019)

Has HTG Molecular Diagnostics been receiving favorable news coverage?

Media headlines about HTGM stock have been trending somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. HTG Molecular Diagnostics earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutHTG Molecular Diagnostics.

Who are some of HTG Molecular Diagnostics' key competitors?

Some companies that are related to HTG Molecular Diagnostics include Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Precipio (PRPO), Scientific Industries (SCND), Arrayit (ARYC), Pressure Biosciences (PBIO) and PositiveID (PSID). View all competitors.

What other stocks do shareholders of HTG Molecular Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Aurinia Pharmaceuticals (AUPH), Proteostasis Therapeutics (PTI), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), CymaBay Therapeutics (CBAY), FleetMatics Group (FLTX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Marinus Pharmaceuticals (MRNS).

Who are HTG Molecular Diagnostics' key executives?

HTG Molecular Diagnostics' management team includes the following people:

Mr. John L. Lubniewski, Pres, CEO & Director (Age 55)
Mr. Shaun D. McMeans, Sr. VP of Fin. & Admin., CFO, Sec. & Treasurer (Age 57)
Dr. Maureen T. Cronin, Sr. VP & Chief Scientific Officer (Age 66)
Dr. Debra A. Gordon, Sr. VP & Chief Legal Counsel (Age 59)
Mr. Sam M. Rua Jr., Sr. VP of Regulatory Affairs & Quality Systems (Age 59)

When did HTG Molecular Diagnostics IPO?

(HTGM) raised $50 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is HTG Molecular Diagnostics' stock symbol?

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

Who are HTG Molecular Diagnostics' major shareholders?

HTG Molecular Diagnostics' stock is owned by many different retail and institutional investors. Top institutional investors include Cowen Prime Services LLC (7.63%), Perkins Capital Management Inc. (4.17%), Stonepine Capital Management LLC (1.70%), BlackRock Inc. (0.80%), First Manhattan Co. (0.28%) and Squarepoint Ops LLC (0.16%). View institutional ownership trends for HTG Molecular Diagnostics.

Which institutional investors are selling HTG Molecular Diagnostics stock?

HTGM stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, and Perkins Capital Management Inc.. View insider buying and selling activity for HTG Molecular Diagnostics.

Which institutional investors are buying HTG Molecular Diagnostics stock?

HTGM stock was bought by a variety of institutional investors in the last quarter, including Cowen Prime Services LLC, Squarepoint Ops LLC, First Manhattan Co., and BlackRock Inc.. View insider buying and selling activity for HTG Molecular Diagnostics.

How do I buy shares of HTG Molecular Diagnostics?

Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is HTG Molecular Diagnostics' stock price today?

One share of HTGM stock can currently be purchased for approximately $0.70.

How big of a company is HTG Molecular Diagnostics?

HTG Molecular Diagnostics has a market capitalization of $43.55 million and generates $19.20 million in revenue each year. The medical research company earns $-19,300,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. HTG Molecular Diagnostics employs 107 workers across the globe.

What is HTG Molecular Diagnostics' official website?

The official website for HTG Molecular Diagnostics is www.htgmolecular.com.

How can I contact HTG Molecular Diagnostics?

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.

This page was last updated on 6/7/2020 by MarketBeat.com Staff